Vicplas International (SGX:569) Total Operating Expense: S$72.3 Mil (TTM As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Vicplas International Total Operating Expense?

Vicplas International SGX:569 Total Operating Expense is S$72.3 Mil as of Jan. 2026. The stock has 5 warning signs investors should review.

Vicplas International's Total Operating Expense for the six months ended in Jan. 2026 was S$36.1 Mil. Vicplas International's Total Operating Expense for the trailing twelve months (TTM) ended in Jan. 2026 was S$72.3 Mil.

Vicplas International Total Operating Expense Related Terms

Vicplas International Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Vicplas International's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicplas International Total Operating Expense Chart

Vicplas International Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.68 62.04 62.22 57.31 64.70

Vicplas International Semi-Annual Data
Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23 Jan24 Jul24 Jan25 Jul25 Jan26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.30 30.54 30.03 36.25 36.05

Vicplas International Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jan. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was S$72.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of S$72.3 Mil mean?
Vicplas International (SGX:569) has a Total Operating Expense of S$72.3 Mil as of Jan. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Vicplas International and its competitors.
Is Vicplas International's Total Operating Expense too high?
Vicplas International's current Total Operating Expense is S$72.3 Mil.
How does Vicplas International's Total Operating Expense compare to ABT and SYK?
Vicplas International's Total Operating Expense of S$72.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Medical Devices & Instruments company?
A good Total Operating Expense depends on the Medical Devices & Instruments industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Vicplas International and its competitors. Vicplas International's current Total Operating Expense is S$72.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicplas International stock overvalued right now?
Based on GuruFocus' analysis, Vicplas International (SGX:569) is currently considered Possible Value Trap. The stock's GF Value™ is S$0.11, compared to a current price of S$0.08 — trading 30% below its estimated fair value. The current Total Operating Expense is S$72.3 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Vicplas International (SGX:569), the current Total Operating Expense is S$72.3 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vicplas International Business Description

Address 35 Joo Koon Circle, Singapore, SGP, 629110
Vicplas International Ltd is an investment holding company. The company is organized into two main business activities: the Pipes and Pipe Fitting segment and the Medical Devices segment, which is the key revenue driver. Pipes and Pipe Fittings segment engages in the manufacturing and distribution of plastic building products, including uPVC pipes and pipe fittings and electrical conduits. The Medical device segment is involved in the research, design, development, and manufacture of medical devices. The company generates majority of its revenue from medical devices. The company does its sales through geographical segments that include Singapore, Malaysia, Mexico, China, and the United Kingdom, of which the majority of the revenue comes from Singapore.